LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 9 von insgesamt 9

Suchoptionen

  1. Artikel ; Online: Sarcomes utérins du stroma de haut grade et sarcomes indifférenciés – Référentiels de prise en charge du Groupe Sarcome Français et du Groupe des Tumeurs Rares Gynécologiques.

    Roussel-Simonin, Cyril / Croce, Sabrina / Guyon, Frédéric / Llacer, Carmen / Ray-Coquard, Isabelle / Meeus, Pierre / Genestie, Catherine / Taieb, Sophie / Malhaire, Caroline / Duffaud, Florence / Pautier, Patricia

    Bulletin du cancer

    2023  Band 110, Heft 7-8, Seite(n) 855–864

    Abstract: High-grade endometrial stromal sarcoma (HGESS) and uterine undifferentiated sarcoma (UUS) are rare uterine malignancies arising from mesenchymal endometrial cells. They are characterized by aggressive behavior and poor prognosis. Median age of diagnostic ...

    Titelübersetzung Uterin sarcoma, high-grade stroma, indifferenciated, referential.
    Abstract High-grade endometrial stromal sarcoma (HGESS) and uterine undifferentiated sarcoma (UUS) are rare uterine malignancies arising from mesenchymal endometrial cells. They are characterized by aggressive behavior and poor prognosis. Median age of diagnostic is 55years. The most common symptoms are vaginal bleeding, abdominal pain, and pelvic mass. Approximately 65 % are diagnosed witch advance disease stage III or IV according to the International Federation of Gynecology and Obstetrics classification. Median overall survival is around 20months. The management of the disease must be discussed in multidisciplinary staff meetings. The standard management of HGESS and UUS is total hysterectomy with bilateral oophorectomy. Systematic lymphadenectomy is not recommended. Adjuvant therapies, such as chemotherapy and radiotherapy must be discussed. In case of oligo-metastasic disease, surgery of the primary tumor and metastasis must be discussed and if not operable the standard management is doxorubine-based chemotherapy.
    Mesh-Begriff(e) Female ; Humans ; Middle Aged ; Uterine Neoplasms/surgery ; Sarcoma/surgery ; Combined Modality Therapy ; Hysterectomy ; Ovariectomy ; Endometrial Neoplasms/therapy ; Endometrial Neoplasms/pathology ; Neoplasm Staging
    Sprache Französisch
    Erscheinungsdatum 2023-04-14
    Erscheinungsland France
    Dokumenttyp English Abstract ; Practice Guideline
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2023.03.017
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel: Evaluation of response after SBRT for liver tumors.

    Tétreau, Raphael / Llacer, Carmen / Riou, Olivier / Deshayes, Emmanuel

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

    2015  Band 22, Heft 2, Seite(n) 170–175

    Abstract: Stereotactic body radiotherapy (SBRT) has developed over the last few years for the treatment of primary and metastatic hepatic tumors. The tumoral and adjacent peritumoral modifications caused by this radiosurgery limit the evaluation of response by ... ...

    Abstract Stereotactic body radiotherapy (SBRT) has developed over the last few years for the treatment of primary and metastatic hepatic tumors. The tumoral and adjacent peritumoral modifications caused by this radiosurgery limit the evaluation of response by anatomic imaging and dimensional criteria alone, such as with RECIST. This suggests that it is of interest to also take into account the residual enhancement and hyper metabolism of these hepatic targets. We have reviewed the English language literature regarding the response of hepatic lesions treated by SBRT, and found that only seven articles were specifically concerned with this problem. The response of the hepatocellular carcinoma after SBRT has been studied specifically with multiphase enhanced CT-scan. Criteria set by the European Association of Study of the Liver better estimate response at each time point of follow up than RECIST does. Non-enhancement, reflecting tumor necrosis, is additionally an early indicator of response with extended response in time and a best non-enhancement percentage is observed at 12 months. The response after treatment by SBRT of cholangiocarcinoma has not yet generated a specific report. Use of RECIST criteria is also inadequate in the evaluation of response after SBRT for hepatic metastases. Response of liver metastases to SBRT is better assessed with a combination of size and enhancement pattern. The occurrence of a lobulated enhancement during follow up is efficient to predict local progression in a specific, reproducible, and sensitive way. Patients with FDG-avid hepatic metastases are also better evaluated with PET-CT and functional criteria than routine imaging and metric evaluation alone.
    Sprache Englisch
    Erscheinungsdatum 2015-12-30
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 2188087-6
    ISSN 1507-1367
    ISSN 1507-1367
    DOI 10.1016/j.rpor.2015.12.004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français.

    Penel, Nicolas / Bonvalot, Sylvie / Minard, Véronique / Orbach, Daniel / Gouin, François / Corradini, Nadège / Brahmi, Mehdi / Marec-Berard, Perrine / Briand, Sylvain / Gaspar, Nathalie / Llacer, Carmen / Carrere, Sébastien / Dufresne, Armelle / Le Cesne, Axel / Blay, Jean-Yves

    Bulletin du cancer

    2020  Band 107, Heft 4, Seite(n) 398–399

    Titelübersetzung French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak.
    Mesh-Begriff(e) Betacoronavirus ; COVID-19 ; Coronavirus Infections/epidemiology ; Disease Outbreaks ; Humans ; Pandemics ; Pneumonia, Viral/epidemiology ; SARS-CoV-2 ; Sarcoma/therapy ; Soft Tissue Neoplasms/therapy
    Schlagwörter covid19
    Sprache Französisch
    Erscheinungsdatum 2020-04-01
    Erscheinungsland France
    Dokumenttyp Letter
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2020.03.009
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du Groupe Sarcome Français

    Penel, Nicolas / Bonvalot, Sylvie / Minard, Véronique / Orbach, Daniel / Gouin, François / Corradini, Nadège / Brahmi, Mehdi / Marec-Berard, Perrine / Briand, Sylvain / Gaspar, Nathalie / Llacer, Carmen / Carrere, Sébastien / Dufresne, Armelle / Le Cesne, Axel / Blay, Jean-Yves

    Bulletin du Cancer

    Schlagwörter covid19
    Verlag Elsevier
    Dokumenttyp Artikel ; Online
    DOI 10.1016/j.bulcan.2020.03.009
    Datenquelle COVID19

    Kategorien

  5. Artikel: Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français./ [French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak]

    Penel, Nicolas / Bonvalot, Sylvie / Minard, Véronique / Orbach, Daniel / Gouin, François / Corradini, Nadège / Brahmi, Mehdi / Marec-Berard, Perrine / Briand, Sylvain / Gaspar, Nathalie / Llacer, Carmen / Carrere, Sébastien / Dufresne, Armelle / Le Cesne, Axel / Blay, Jean-Yves

    Bull Cancer

    Schlagwörter covid19
    Verlag WHO
    Dokumenttyp Artikel
    Anmerkung WHO #Covidence: #23254
    Datenquelle COVID19

    Kategorien

  6. Artikel ; Online: Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19

    Penel, Nicolas / Bonvalot, Sylvie / Minard, Véronique / Orbach, Daniel / Gouin, François / Corradini, Nadège / Brahmi, Mehdi / Marec-Berard, Perrine / Briand, Sylvain / Gaspar, Nathalie / Llacer, Carmen / Carrere, Sébastien / Dufresne, Armelle / Le Cesne, Axel / Blay, Jean-Yves

    Bulletin du Cancer

    propositions du groupe sarcome français

    2020  Band 107, Heft 4, Seite(n) 398–399

    Schlagwörter Cancer Research ; Oncology ; Radiology Nuclear Medicine and imaging ; Hematology ; General Medicine ; covid19
    Sprache Französisch
    Verlag Elsevier BV
    Erscheinungsland us
    Dokumenttyp Artikel ; Online
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2020.03.009
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.

    Ducreux, Michel / Giovannini, Marc / Baey, Charlotte / Llacer, Carmen / Bennouna, Jaafar / Adenis, Antoine / Peiffert, Didier / Mornex, Françoise / Abbas, Moncef / Boige, Valèrie / Pignon, Jean-Pierre / Conroy, Thierry / Cellier, Patrice / Juzyna, Beata / Viret, Frédéric

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

    2014  Band 46, Heft 10, Seite(n) 950–955

    Abstract: Background: We performed a randomized, non-comparative phase II study evaluating docetaxel in combination with either daily continuous (protracted IV) 5-fluorouracil or cisplatin administered weekly, concurrent to radiotherapy in the treatment of ... ...

    Abstract Background: We performed a randomized, non-comparative phase II study evaluating docetaxel in combination with either daily continuous (protracted IV) 5-fluorouracil or cisplatin administered weekly, concurrent to radiotherapy in the treatment of locally advanced pancreatic carcinoma. Results of the docetaxel plus cisplatin regimen are reported.
    Methods: Forty chemotherapy-naive patients with locally advanced pancreatic carcinoma were randomly assigned to receive 5-fluorouracil and docetaxel or docetaxel 20mg/m(2) and cisplatin 20mg/m(2)/week, plus concurrent radiotherapy for 6 weeks. The radiation dose to the primary tumour was 54Gy in 30 fractions. The trial's primary endpoint was the 6-month crude non-progression rate.
    Results: 51 patients from 7 centres were included in the docetaxel-cisplatin treatment group. Six-month non-progression rate was 39% (95% confidence interval: 26-53). Median overall survival was 9.6 months (95% confidence interval: 2.4-60.7); 6 complete and 8 partial responses were obtained. Six patients survived more than 2 years after their inclusion in the trial. Grade ≥3 toxicity was reported in 63% of patients; no treatment-related death occurred. Severe toxicities were mainly anorexia (22%), vomiting (20%) and fatigue (24%).
    Conclusions: Despite inadequate efficacy according to the main end point, this regimen gave a satisfactory rate of objective response (27%) with tolerable toxicity.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy ; Cisplatin/administration & dosage ; Docetaxel ; Drug Administration Schedule ; Female ; Fluorouracil/administration & dosage ; Humans ; Male ; Middle Aged ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/therapy ; Survival Analysis ; Taxoids/administration & dosage ; Treatment Outcome ; Young Adult ; Pancreatic Neoplasms
    Chemische Substanzen Antineoplastic Agents ; Taxoids ; Docetaxel (15H5577CQD) ; Cisplatin (Q20Q21Q62J) ; Fluorouracil (U3P01618RT)
    Sprache Englisch
    Erscheinungsdatum 2014-07-12
    Erscheinungsland Netherlands
    Dokumenttyp Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1459373-7
    ISSN 1878-3562 ; 1125-8055
    ISSN (online) 1878-3562
    ISSN 1125-8055
    DOI 10.1016/j.dld.2014.06.006
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel: Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure.

    Llácer, Carmen / Delannes, Martine / Minsat, Mathieu / Stoeckle, Eberhard / Votron, Laurent / Martel, Pierre / Bonnevialle, Paul / Nguyen Bui, Binh / Chevreau, Christine / Kantor, Guy / Daly-Schveitzer, Nicolas / Thomas, Laurence

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

    2006  Band 78, Heft 1, Seite(n) 10–16

    Abstract: Background and purpose: To evaluate intraoperative brachytherapy in the management of soft tissue sarcomas involving neurovascular structures, its impact on local control and complications.: Patients and methods: Between 01/1989 and 12/2002, 98 ... ...

    Abstract Background and purpose: To evaluate intraoperative brachytherapy in the management of soft tissue sarcomas involving neurovascular structures, its impact on local control and complications.
    Patients and methods: Between 01/1989 and 12/2002, 98 patients received an intraoperative implant in conjunction with conservative surgery. Brachytherapy was part of the initial treatment (79 cases) or performed in recurrent disease (19 cases). We studied primary sarcomas involving neurovascular structures treated with conservative surgery and intraoperative brachytherapy (n = 6) or intraoperative brachytherapy and external irradiation (n = 73). Conservative surgery was performed as first treatment (51 cases), after chemotherapy (21 cases) and after primary external radiation (seven cases). Brachytherapy was performed according to Paris system rules. Patients were loaded with Iridium 192 (64 cases) or connected to a Microselectron PDR (15 cases). Mean dose given by brachytherapy was 20 Gy. Mean dose given of external radiotherapy was 46 Gy.
    Results: With a median follow-up of 58 months, 5-year actuarial survival was 69% and local free disease at 5 years was 90%. Acute side-effects occurred in 22/79 requiring surgical repair in 10 patients. Late side-effects occurred in 35/79. No patient required amputation for complications. Prognostic factors were studied for the occurrence of acute and late side-effects and local control.
    Conclusions: Intraoperative brachytherapy is efficient with excellent local control rates in soft tissue sarcomas presenting with neurovascular involvement and offers an acceptable conservative option.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Brachytherapy/adverse effects ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Intraoperative Period ; Iridium Radioisotopes/therapeutic use ; Male ; Middle Aged ; Sarcoma/drug therapy ; Sarcoma/radiotherapy ; Sarcoma/surgery ; Soft Tissue Neoplasms/drug therapy ; Soft Tissue Neoplasms/radiotherapy ; Soft Tissue Neoplasms/surgery ; Survival Analysis
    Chemische Substanzen Iridium Radioisotopes
    Sprache Englisch
    Erscheinungsdatum 2006-01
    Erscheinungsland Ireland
    Dokumenttyp Evaluation Studies ; Journal Article
    ZDB-ID 605646-5
    ISSN 1879-0887 ; 0167-8140
    ISSN (online) 1879-0887
    ISSN 0167-8140
    DOI 10.1016/j.radonc.2005.12.002
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Livre blanc de la radiothérapie en France 2013. Douze objectifs pour améliorer un des traitements majeurs du cancer.

    Chauvet, B / Mahé, M-A / Maingon, P / Mazeron, J-J / Mornex, F / Chauvet, Bruno / Mahé, Marc-André / Maingon, Philippe / Mazeron, Jean-Jacques / Mornex, Françoise / Azria, David / Barillot, Isabelle / Denis, Fabrice / Lartigau, Éric / Lipinski, Francis / Ardiet, Jean-Michel / Bibault, Jean-Emmanuel / Caudrelier, Valérie / Diaz, Olivia /
    de Crevoisier, Renaud / Dubray, Bernard / Estivalet, Stéphane / Faivre, Jean-Christophe / Fenoglietto, Pascal / Fumagalli, Ingrid / Ferlay, Jacques / Giraud, Philippe / Hennequin, Christophe / Henoch, Hervé / Khodri, Mustapha / Llacer, Carmen / Lagrange, Jean-Léon / Lorchel, Fabrice / Meyrieux, Charlotte / de Martel, Catherine / Noël, Georges / Oozeer, Rashid / Peiffert, Didier / Pointreau, Yoann / Pourel, Nicolas / Pradier, Olivier / Rocher, François / Thureau, Sébastien / Eschwège, François / Martin, Philippe / Parmentier, Gérard

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2013  Band 17 Suppl 1, Seite(n) S2–72

    Titelübersetzung White paper on radiation oncology in France. Twelve proposals to improve a major cancer treatment. Société française de radiothérapie oncologique.
    Mesh-Begriff(e) Clinical Trials as Topic ; Diffusion of Innovation ; Financing, Organized/legislation & jurisprudence ; France ; Government Agencies ; Health Services Accessibility/legislation & jurisprudence ; Health Services Accessibility/trends ; Humans ; Informed Consent/legislation & jurisprudence ; Interdisciplinary Communication ; Neoplasms/radiotherapy ; Patient Education as Topic/standards ; Quality Assurance, Health Care ; Quality Improvement ; Radiation Injuries/etiology ; Radiation Injuries/prevention & control ; Radiation Oncology/education ; Radiation Oncology/manpower ; Radiation Oncology/organization & administration ; Radiation Oncology/trends ; Radiosurgery ; Radiotherapy/adverse effects ; Radiotherapy/economics ; Radiotherapy/ethics ; Radiotherapy/instrumentation ; Radiotherapy/methods ; Radiotherapy/standards ; Radiotherapy/trends ; Radiotherapy Dosage ; Research ; Risk Management ; Societies, Medical ; Societies, Scientific ; Socioeconomic Factors ; Staff Development ; Technology, High-Cost ; Translational Medical Research
    Sprache Französisch
    Erscheinungsdatum 2013-08
    Erscheinungsland France
    Dokumenttyp Journal Article ; Practice Guideline
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2013.04.002
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang